$RXRX insider trading
Over the last 12 months, Recursion Pharmaceuticals insiders reported no purchases and 36 sales totaling $8.9M across SEC Form 4 filings. 100% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $8.9M 36 events
- Events · 12m
- 36 Form 4 filings, grouped
- Insiders · 12m
- 5 distinct reporters
- 10b5-1 share
- 100% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Khan NajatCEO and President · O·D | ▼ Sale | 22,408 | $3.52 | $79K | -1.1% | plan |
| Sep 1, 2026 | Borgeson BlakeD | ▼ Sale | 30,000 | $3.34 | $100K | -0.5% | plan |
| Aug 4, 2026 | Borgeson BlakeD | ▼ Sale | 30,000 | $3.25 | $98K | -0.5% | plan |
| Jul 7, 2026 | Borgeson BlakeD | ▼ Sale | 40,000 | $3.96 | $159K | -0.6% | plan |
| Jun 18, 2026 | Bumpus NamandjeD | ▼ Sale | 3,963 | $3.18 | $13K | -3% | plan |
| Jun 5, 2026 | Gibson ChristopherD | ▼ Sale | 40,000 | $3.62 | $145K | -4.3% | plan |
| Jun 5, 2026 | Khan NajatCEO and President · O·D | ▼ Sale | 23,588 | $3.58 | $84K | -1.1% | plan |
| Jun 3, 2026 | Bumpus NamandjeD | ▼ Sale | 4,386 | $3.54 | $16K | -9.2% | plan |
| Jun 2, 2026 | Borgeson BlakeD | ▼ Sale | 30,000 | $3.68 | $110K | -0.5% | plan |
| May 22, 2026 | Gibson ChristopherD | ▼ Sale | 40,000 | $3.08 | $123K | -4.3% | plan |
| May 7, 2026 | Gibson ChristopherD | ▼ Sale | 40,000 | $3.37 | $135K | -4.1% | plan |
| May 5, 2026 | Borgeson BlakeD | ▼ Sale | 30,000 | $3.52 | $106K | -0.5% | plan |
| Apr 22, 2026 | Gibson ChristopherD | ▼ Sale | 40,000 | $3.61 | $144K | -4.2% | plan |
| Apr 7, 2026 | Gibson ChristopherD | ▼ Sale | 40,000 | $3.1 | $124K | -4.2% | plan |
| Apr 7, 2026 | Borgeson BlakeD | ▼ Sale | 30,000 | $3.1 | $93K | -0.5% | plan |
| Mar 23, 2026 | Gibson ChristopherD | ▼ Sale | 40,000 | $3.25 | $130K | -4.2% | plan |
| Mar 17, 2026 | Taylor Ben RChief Financial Officer · O | ▼ Sale | 7,956 | $3.39 | $27K | -0.7% | plan |
| Mar 9, 2026 | Khan NajatCEO and President · O·D | ▼ Sale | 28,298 | $3.35 | $95K | -1.2% | plan |
| Mar 3, 2026 | Borgeson BlakeD | ▼ Sale | 170,000 | $3.46 | $588K | -2.6% | plan |
| Feb 19, 2026 | Gibson ChristopherD | ▼ Sale | 40,000 | $3.46 | $138K | -4.2% | plan |
| Feb 18, 2026 | Taylor Ben RChief Financial Officer · O | ▼ Sale | 13,426 | $3.08 | $41K | -1.1% | plan |
| Feb 4, 2026 | Gibson ChristopherD | ▼ Sale | 40,000 | $4.12 | $165K | -4.2% | plan |
| Feb 3, 2026 | Borgeson BlakeD | ▼ Sale | 220,000 | $4.2 | $924K | -3.3% | plan |
| Jan 20, 2026 | Gibson ChristopherD | ▼ Sale | 40,000 | $4.47 | $179K | -4.2% | plan |
| Jan 6, 2026 | Borgeson BlakeD | ▼ Sale | 220,000 | $4.36 | $959K | -3.2% | plan |
| Jan 5, 2026 | Gibson ChristopherD | ▼ Sale | 40,000 | $4.25 | $170K | -4.1% | plan |
| Dec 29, 2025 | Taylor Ben RChief Financial Officer · O | ▼ Sale | 21,383 | $4.18 | $89K | -2.7% | plan |
| Dec 22, 2025 | Khan NajatChief R&D Commercial Officer · O·D | ▼ Sale | 124,403 | $4.41 | $549K | -16.9% | plan · late |
| Dec 19, 2025 | Gibson ChristopherChief Executive Officer · O·D | ▼ Sale | 40,000 | $4.5 | $180K | -4.2% | plan |
| Dec 4, 2025 | Gibson ChristopherChief Executive Officer · O·D | ▼ Sale | 40,000 | $4.63 | $185K | -4.1% | plan |
| Dec 2, 2025 | Borgeson BlakeD | ▼ Sale | 220,000 | $4.37 | $961K | -3.1% | plan |
| Nov 19, 2025 | Gibson ChristopherChief Executive Officer · O·D | ▼ Sale | 40,000 | $4.16 | $166K | -4.2% | plan |
| Nov 4, 2025 | Gibson ChristopherChief Executive Officer · O·D | ▼ Sale | 40,000 | $5.21 | $208K | -3.9% | plan |
| Oct 23, 2025 | Gibson ChristopherChief Executive Officer · O·D | ▼ Sale | 100,000 | $5.7 | $570K | -9.5% | plan |
| Oct 10, 2025 | Gibson ChristopherChief Executive Officer · O·D | ▼ Sale | 100,000 | $6.04 | $604K | -9.3% | plan |
| Sep 25, 2025 | Gibson ChristopherChief Executive Officer · O·D | ▼ Sale | 100,000 | $4.76 | $476K | -9.5% | plan |
| Sep 10, 2025 | Gibson ChristopherChief Executive Officer · O·D | ▼ Sale | 100,000 | $4.71 | $471K | -9.3% | plan |
| Aug 26, 2025 | Gibson ChristopherChief Executive Officer · O·D | ▼ Sale | 100,000 | $4.84 | $484K | -9.5% | plan |
| Aug 18, 2025 | Khan NajatChief R&D Commercial Officer · O·D | ▼ Sale | 36,599 | $5.52 | $202K | -5.2% | — |
| Aug 11, 2025 | Gibson ChristopherChief Executive Officer · O·D | ▼ Sale | 117,875 | $5.28 | $622K | -100% | plan · 2 tranches · indirect |
| Aug 11, 2025 | Gibson ChristopherChief Executive Officer · O·D | ▼ Sale | 500,300 | $5.28 | $2.6M | -33.2% | plan |
Every $RXRX filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Recursion Pharmaceuticals filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $RXRX feed.